Curing Autism, Epilepsy & Schizophrenia with Stem Cells | Dr. Sergiu Pașca

Yes, autism is more prevalent in males, with a ratio of about 4:1 compared to females. While diagnostic biases and masking behaviors in girls might play a role, biological differences in brain maturation and resilience, possibly linked to the SRY gene, are also considered contributing factors.

Genetics play a strong role in autism, with hundreds of associated genes. These genes can encode proteins for synapses (synaptopathies), ion channels (channelopathies), or DNA packing (chromatinopathies). These genetic variations can disrupt nervous system development and contribute to autism's complex biology.

Key challenges stem from the human brain's inaccessibility and the lack of precise biological markers for disorders like autism, which are often defined behaviorally. This disconnect makes molecular understanding and targeted therapeutic development difficult, leading to slower progress compared to diseases with clear biological definitions.

CRISPR precisely edits DNA, allowing for genetic defect correction. While promising, its application in brain disorders faces challenges: effective delivery to all affected cells, the size of genes that can be carried by viral vectors, and the irreversible nature of genetic modifications, necessitating high precision and safety.

Yamanaka's breakthrough allowed adult skin cells to be reprogrammed into iPSCs using specific genetic factors. This eliminated the need for embryonic stem cells, sidestepping ethical debates and providing an unlimited, patient-specific source of pluripotent cells for modeling diseases and developing therapies.

Unproven stem cell injections, often sought abroad by desperate parents, carry significant risks. These include unknown cell origins, lack of biological rationale for conditions like autism, and potential adverse effects such as infection, paralysis, or even permanent vision loss, as these procedures are unregulated and lack scientific validation.

Brain organoids are 3D cultures that recapitulate human brain development, including an intrinsic developmental clock. Assemblids combine different organoids to create complex neural circuits, allowing researchers to study long-distance neuronal interactions and emergent properties relevant to psychiatric and neurological disorders.

Assemblids have been instrumental in modeling Timothy Syndrome, revealing specific defects in calcium channels and leading to a nucleic acid-based therapeutic. They are also used to study intractable epilepsies by mimicking complex neural networks, allowing analysis of genetic mutations and their effects on circuit activity.

Ethical concerns include ensuring informed consent for human cell use, minimizing harm to recipient animals, and addressing potential issues of consciousness or pain in complex neural constructs. Responsible communication, avoiding terms like 'mini-brains,' is crucial to maintain public trust and prevent misinterpretation of research capabilities.

The biological timer is an intrinsic mechanism in human neurons that allows them to keep track of developmental time, even in a dish. This is exemplified by molecular switches occurring at specific developmental time points, like the transition of NMDA receptor subunits at nine months in organoids, mirroring in vivo changes. Understanding this 'timer' holds potential for manipulating cell aging and rejuvenation.

Female premature babies generally exhibit better outcomes than males. This indicates inherent biological differences in brain resilience and maturation rates between sexes, with female nervous systems potentially being more robust or maturing differently, allowing them to better withstand early life challenges.

Societal perceptions and advocacy significantly impact research funding. Autism, often affecting children, garners considerable public sympathy and lobbying, directing more funds. In contrast, schizophrenia, frequently manifesting in adulthood and associated with stigma, has historically received less research investment despite its significant impact.

A therapeutic for Timothy Syndrome, a rare genetic form of autism, is in preparation for clinical trials. This therapeutic, developed exclusively with human stem cell models, involves a small nucleic acid that corrects a calcium channel defect. Its significance lies in being a potential first-in-class treatment for a psychiatric disease developed without animal models, offering hope for highly specific genetic therapies.